{"product_id":"american-society-for-dermatologic-surgery-immunotherapy-for-non-melanoma-skin-cancer","title":"American Society for Dermatologic Surgery Immunotherapy for Non-melanoma Skin Cancer","description":"\u003cdiv class=\"group-header field-group-div clearfix\"\u003e\r\n\u003cdiv class=\"group-header-inner field-group-div\"\u003e\r\n\u003cdiv class=\"group-course-header-right field-group-div\"\u003e\r\n\u003cdiv class=\"field field-name-title field-type-ds field-label-hidden\"\u003e\r\n\u003cdiv class=\"field-items\"\u003e\r\n\u003cdiv class=\"field-item even\"\u003e\r\n\u003cdiv class=\"featured__product__tab__content__item__header\"\u003e\r\n\u003cdiv class=\"featured__product__tab__content__item__header\"\u003e\r\n\u003cdiv class=\"featured__product__tab__content__item__header\"\u003e\r\n\u003cdiv class=\"featured__product__tab__content__item__header\"\u003e\r\n\u003ch1 data-section-id=\"19wjg76\" data-start=\"0\" data-end=\"86\"\u003eAmerican Society for Dermatologic Surgery Immunotherapy for Non-Melanoma Skin Cancer\u003c\/h1\u003e\r\n\u003ch2 data-section-id=\"rtz4h\" data-start=\"88\" data-end=\"150\"\u003eAdvanced Immunotherapy Updates for Non-Melanoma Skin Cancer\u003c\/h2\u003e\r\n\u003cp data-start=\"152\" data-end=\"378\"\u003eThe \u003cstrong data-start=\"156\" data-end=\"251\"\u003eAmerican Society for Dermatologic Surgery (ASDS) Immunotherapy for Non-Melanoma Skin Cancer\u003c\/strong\u003e program provides a focused review of the growing role of immunotherapy in the treatment of advanced non-melanoma skin cancers.\u003c\/p\u003e\r\n\u003cp data-start=\"380\" data-end=\"778\"\u003eAs immune checkpoint inhibitors continue to transform cancer care, dermatologists, dermatologic surgeons, and oncologists must remain current with emerging evidence, treatment indications, clinical outcomes, and safety considerations. This educational activity uses real-world patient cases to illustrate how immunotherapy is being incorporated into the management of challenging skin cancer cases.\u003c\/p\u003e\r\n\u003cp data-start=\"780\" data-end=\"1001\"\u003eThe webinar reviews current clinical data supporting immunotherapy for non-melanoma skin cancers while addressing patient selection, treatment outcomes, and the recognition and management of immune-related adverse events.\u003c\/p\u003e\r\n\u003cp data-start=\"1003\" data-end=\"1189\"\u003eDesigned for clinicians involved in the treatment of advanced skin cancers, this program delivers practical, evidence-based insights that can be immediately applied to clinical practice.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"1191\" data-end=\"1194\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1gr0678\" data-start=\"1196\" data-end=\"1217\"\u003e📦 Course Features\u003c\/h2\u003e\r\n\u003cul data-start=\"1219\" data-end=\"1421\"\u003e\r\n \t\u003cli data-section-id=\"1kmjnzo\" data-start=\"1219\" data-end=\"1236\"\u003e1 Video Lecture\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1eiykjz\" data-start=\"1237\" data-end=\"1257\"\u003eTotal Size: 126 MB\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1xen3ds\" data-start=\"1258\" data-end=\"1287\"\u003eExpert Faculty Presentation\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1x43j4l\" data-start=\"1288\" data-end=\"1315\"\u003eReal-World Clinical Cases\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1gdllvf\" data-start=\"1316\" data-end=\"1354\"\u003eEvidence-Based Immunotherapy Updates\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"mblc63\" data-start=\"1355\" data-end=\"1387\"\u003eAdvanced Skin Cancer Education\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1isjkfx\" data-start=\"1388\" data-end=\"1421\"\u003ePractical Clinical Applications\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"1423\" data-end=\"1426\"\u003e\r\n\r\n\u003ch2 data-section-id=\"12iwxhe\" data-start=\"1428\" data-end=\"1452\"\u003e👨‍⚕️ Target Audience\u003c\/h2\u003e\r\n\u003cp data-start=\"1454\" data-end=\"1479\"\u003eThis course is ideal for:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1481\" data-end=\"1676\"\u003e\r\n \t\u003cli data-section-id=\"1gctjbp\" data-start=\"1481\" data-end=\"1497\"\u003eDermatologists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"shitxi\" data-start=\"1498\" data-end=\"1521\"\u003eDermatologic Surgeons\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"z675uk\" data-start=\"1522\" data-end=\"1535\"\u003eOncologists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"50uhw5\" data-start=\"1536\" data-end=\"1551\"\u003eMohs Surgeons\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1cjtysl\" data-start=\"1552\" data-end=\"1584\"\u003eCutaneous Oncology Specialists\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1fmw1r\" data-start=\"1585\" data-end=\"1614\"\u003eAdvanced Practice Providers\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"18vu5xr\" data-start=\"1615\" data-end=\"1676\"\u003eHealthcare Professionals Involved in Skin Cancer Management\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"1678\" data-end=\"1729\"\u003eIt is particularly valuable for clinicians seeking:\u003c\/p\u003e\r\n\u003cp data-start=\"1731\" data-end=\"1773\"\u003e✔ Updates on Immunotherapy for Skin Cancer\u003c\/p\u003e\r\n\u003cp data-start=\"1775\" data-end=\"1814\"\u003e✔ Immune Checkpoint Inhibitor Education\u003c\/p\u003e\r\n\u003cp data-start=\"1816\" data-end=\"1862\"\u003e✔ Advanced Non-Melanoma Skin Cancer Management\u003c\/p\u003e\r\n\u003cp data-start=\"1864\" data-end=\"1895\"\u003e✔ Dermatologic Oncology Updates\u003c\/p\u003e\r\n\u003cp data-start=\"1897\" data-end=\"1937\"\u003e✔ Adverse Event Recognition \u0026amp; Management\u003c\/p\u003e\r\n\u003cp data-start=\"1939\" data-end=\"1976\"\u003e✔ Evidence-Based Treatment Strategies\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"1978\" data-end=\"1981\"\u003e\r\n\r\n\u003ch2 data-section-id=\"mm7n7w\" data-start=\"1983\" data-end=\"2005\"\u003e🧠 Program Overview\u003c\/h2\u003e\r\n\u003cp data-start=\"2007\" data-end=\"2243\"\u003eNon-melanoma skin cancers are among the most common malignancies worldwide. While most cases are effectively managed with surgery and local therapies, advanced, recurrent, or metastatic disease may require systemic treatment approaches.\u003c\/p\u003e\r\n\u003cp data-start=\"2245\" data-end=\"2560\"\u003eRecent advances in immunotherapy have significantly expanded treatment options for patients with advanced non-melanoma skin cancers. Immune checkpoint inhibitors have demonstrated meaningful clinical benefits in selected patients and have become an increasingly important component of modern skin cancer management.\u003c\/p\u003e\r\n\u003cp data-start=\"2562\" data-end=\"2771\"\u003eThis webinar provides a practical review of currently available immunotherapies, summarizes key clinical data, and explores how immunotherapy is being integrated into real-world dermatologic oncology practice.\u003c\/p\u003e\r\n\u003cp data-start=\"2773\" data-end=\"2952\"\u003eThrough case-based discussions and expert analysis, participants gain valuable insight into treatment selection, expected outcomes, and management of treatment-related toxicities.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"2954\" data-end=\"2957\"\u003e\r\n\r\n\u003ch2 data-section-id=\"gtrs66\" data-start=\"2959\" data-end=\"2984\"\u003e🎯 Learning Objectives\u003c\/h2\u003e\r\n\u003cp data-start=\"2986\" data-end=\"3049\"\u003eUpon completion of this activity, participants will be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3051\" data-end=\"3573\"\u003e\r\n \t\u003cli data-section-id=\"1q2iumo\" data-start=\"3051\" data-end=\"3121\"\u003eDefine non-melanoma skin cancers that may benefit from immunotherapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"unhgoj\" data-start=\"3122\" data-end=\"3199\"\u003eSummarize currently available immunotherapies for non-melanoma skin cancers\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1gqe546\" data-start=\"3200\" data-end=\"3283\"\u003eReview the role of immune checkpoint inhibitors in advanced skin cancer treatment\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"hbp5oa\" data-start=\"3284\" data-end=\"3341\"\u003eDiscuss clinical outcomes associated with immunotherapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1kcnhy1\" data-start=\"3342\" data-end=\"3390\"\u003eRecognize common immune-related adverse events\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1jpi7km\" data-start=\"3391\" data-end=\"3458\"\u003eApply evidence-based treatment strategies to appropriate patients\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"12aqgro\" data-start=\"3459\" data-end=\"3504\"\u003eImprove patient selection for immunotherapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"13c0p91\" data-start=\"3505\" data-end=\"3573\"\u003eIntegrate emerging immunotherapy approaches into clinical practice\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"3575\" data-end=\"3578\"\u003e\r\n\r\n\u003ch2 data-section-id=\"dzhb13\" data-start=\"3580\" data-end=\"3605\"\u003e🧩 Core Topics Covered\u003c\/h2\u003e\r\n\u003ch3 data-section-id=\"vk7l98\" data-start=\"3607\" data-end=\"3656\"\u003e🧬 Immunotherapy for Non-Melanoma Skin Cancer\u003c\/h3\u003e\r\n\u003cp data-start=\"3658\" data-end=\"3678\"\u003eParticipants review:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3680\" data-end=\"3850\"\u003e\r\n \t\u003cli data-section-id=\"1enco76\" data-start=\"3680\" data-end=\"3716\"\u003ePrinciples of Cancer Immunotherapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"11ezvz6\" data-start=\"3717\" data-end=\"3747\"\u003eImmune Checkpoint Inhibitors\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1r5p5zr\" data-start=\"3748\" data-end=\"3770\"\u003eMechanisms of Action\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1ptf1ol\" data-start=\"3771\" data-end=\"3801\"\u003eCurrent Treatment Approaches\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1vjn4j\" data-start=\"3802\" data-end=\"3850\"\u003eClinical Applications in Dermatologic Oncology\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"3852\" data-end=\"3855\"\u003e\r\n\r\n\u003ch3 data-section-id=\"1dd6wpp\" data-start=\"3857\" data-end=\"3895\"\u003e🔬 Advanced Skin Cancer Management\u003c\/h3\u003e\r\n\u003cp data-start=\"3897\" data-end=\"3925\"\u003eFocused discussions include:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3927\" data-end=\"4066\"\u003e\r\n \t\u003cli data-section-id=\"t8bmbs\" data-start=\"3927\" data-end=\"3963\"\u003eAdvanced Non-Melanoma Skin Cancers\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1j2octe\" data-start=\"3964\" data-end=\"3990\"\u003eLocally Advanced Disease\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"fwyk41\" data-start=\"3991\" data-end=\"4014\"\u003eRecurrent Skin Cancer\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"f26csh\" data-start=\"4015\" data-end=\"4035\"\u003eMetastatic Disease\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1ynfuli\" data-start=\"4036\" data-end=\"4066\"\u003ePatient Selection Strategies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"4068\" data-end=\"4071\"\u003e\r\n\r\n\u003ch3 data-section-id=\"1akromo\" data-start=\"4073\" data-end=\"4108\"\u003e📈 Clinical Evidence \u0026amp; Outcomes\u003c\/h3\u003e\r\n\u003cp data-start=\"4110\" data-end=\"4131\"\u003eThe program examines:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4133\" data-end=\"4243\"\u003e\r\n \t\u003cli data-section-id=\"f20fov\" data-start=\"4133\" data-end=\"4161\"\u003eCurrent Immunotherapy Data\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"df0xed\" data-start=\"4162\" data-end=\"4182\"\u003eTreatment Outcomes\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"dmug62\" data-start=\"4183\" data-end=\"4199\"\u003eResponse Rates\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"19osl0j\" data-start=\"4200\" data-end=\"4219\"\u003eClinical Benefits\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1kkizlv\" data-start=\"4220\" data-end=\"4243\"\u003eReal-World Experience\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"4245\" data-end=\"4248\"\u003e\r\n\r\n\u003ch3 data-section-id=\"1yhygzf\" data-start=\"4250\" data-end=\"4295\"\u003e⚠️ Adverse Events \u0026amp; Safety Considerations\u003c\/h3\u003e\r\n\u003cp data-start=\"4297\" data-end=\"4322\"\u003eParticipants learn about:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4324\" data-end=\"4465\"\u003e\r\n \t\u003cli data-section-id=\"1d1s7n4\" data-start=\"4324\" data-end=\"4355\"\u003eImmune-Related Adverse Events\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"5xoqa1\" data-start=\"4356\" data-end=\"4381\"\u003eDermatologic Toxicities\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1ue9umw\" data-start=\"4382\" data-end=\"4405\"\u003eSystemic Side Effects\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"15ln9nd\" data-start=\"4406\" data-end=\"4429\"\u003eMonitoring Strategies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"5peyqf\" data-start=\"4430\" data-end=\"4465\"\u003eToxicity Recognition \u0026amp; Management\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"4467\" data-end=\"4470\"\u003e\r\n\r\n\u003ch3 data-section-id=\"o2evpt\" data-start=\"4472\" data-end=\"4507\"\u003e🩺 Case-Based Clinical Learning\u003c\/h3\u003e\r\n\u003cp data-start=\"4509\" data-end=\"4535\"\u003eReal-world cases focus on:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4537\" data-end=\"4676\"\u003e\r\n \t\u003cli data-section-id=\"152gx9o\" data-start=\"4537\" data-end=\"4558\"\u003eTreatment Selection\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"djr5fh\" data-start=\"4559\" data-end=\"4585\"\u003eClinical Decision-Making\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"tn0o68\" data-start=\"4586\" data-end=\"4617\"\u003eChallenging Patient Scenarios\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1patvys\" data-start=\"4618\" data-end=\"4638\"\u003eOutcome Assessment\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1a746lz\" data-start=\"4639\" data-end=\"4676\"\u003eLong-Term Management Considerations\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"4678\" data-end=\"4681\"\u003e\r\n\r\n\u003ch2 data-section-id=\"1n0lan6\" data-start=\"4683\" data-end=\"4709\"\u003e📚 Educational Features\u003c\/h2\u003e\r\n\u003ch3 data-section-id=\"azzdhp\" data-start=\"4711\" data-end=\"4763\"\u003e✔ Evidence-Based Dermatologic Oncology Education\u003c\/h3\u003e\r\n\u003cp data-start=\"4765\" data-end=\"4791\"\u003eThe curriculum integrates:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4793\" data-end=\"4976\"\u003e\r\n \t\u003cli data-section-id=\"yssgzq\" data-start=\"4793\" data-end=\"4825\"\u003eCurrent Immunotherapy Research\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1uqng66\" data-start=\"4826\" data-end=\"4853\"\u003eClinical Practice Updates\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"mnx61m\" data-start=\"4854\" data-end=\"4883\"\u003eReal-World Case Discussions\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"lt9542\" data-start=\"4884\" data-end=\"4917\"\u003eAdvanced Skin Cancer Management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"46qkac\" data-start=\"4918\" data-end=\"4946\"\u003eTreatment Outcome Analysis\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"bkn7vm\" data-start=\"4947\" data-end=\"4976\"\u003ePractical Clinical Guidance\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\r\n\u003chr data-start=\"4978\" data-end=\"4981\"\u003e\r\n\r\n\u003ch3 data-section-id=\"ogslpo\" data-start=\"4983\" data-end=\"5017\"\u003e✔ Expert Clinical Perspectives\u003c\/h3\u003e\r\n\u003cp data-start=\"5019\" data-end=\"5153\"\u003eParticipants learn from specialists experienced in dermatologic surgery, skin cancer treatment, and immunotherapy-based oncology care.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"5155\" data-end=\"5158\"\u003e\r\n\r\n\u003ch3 data-section-id=\"1n4aa8k\" data-start=\"5160\" data-end=\"5196\"\u003e✔ Practical Clinical Application\u003c\/h3\u003e\r\n\u003cp data-start=\"5198\" data-end=\"5370\"\u003eThe activity emphasizes real-world decision-making strategies that can be immediately applied when evaluating and managing patients with advanced non-melanoma skin cancers.\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"5372\" data-end=\"5375\"\u003e\r\n\r\n\u003ch2 data-section-id=\"fcjyt5\" data-start=\"5377\" data-end=\"5408\"\u003e⭐ Why This Course Stands Out\u003c\/h2\u003e\r\n\u003cp data-start=\"5410\" data-end=\"5478\"\u003e✔ Focused Specifically on Immunotherapy for Non-Melanoma Skin Cancer\u003c\/p\u003e\r\n\u003cp data-start=\"5480\" data-end=\"5526\"\u003e✔ Strong Emphasis on Real-World Clinical Cases\u003c\/p\u003e\r\n\u003cp data-start=\"5528\" data-end=\"5582\"\u003e✔ Comprehensive Review of Immune Checkpoint Inhibitors\u003c\/p\u003e\r\n\u003cp data-start=\"5584\" data-end=\"5618\"\u003e✔ Evidence-Based Treatment Updates\u003c\/p\u003e\r\n\u003cp data-start=\"5620\" data-end=\"5667\"\u003e✔ Practical Adverse Event Management Strategies\u003c\/p\u003e\r\n\u003cp data-start=\"5669\" data-end=\"5735\"\u003e✔ Relevant for Dermatologists, Dermatologic Surgeons \u0026amp; Oncologists\u003c\/p\u003e\r\n\u003cp data-start=\"5737\" data-end=\"5767\"\u003e✔ Immediate Clinical Relevance\u003c\/p\u003e\r\n\r\n\r\n\u003chr data-start=\"5769\" data-end=\"5772\"\u003e\r\n\r\n\u003ch2 data-section-id=\"51a47x\" data-start=\"5774\" data-end=\"5808\"\u003e🚀 Clinical \u0026amp; Educational Value\u003c\/h2\u003e\r\n\u003cp data-start=\"5810\" data-end=\"5981\"\u003eThe \u003cstrong data-start=\"5814\" data-end=\"5865\"\u003eASDS Immunotherapy for Non-Melanoma Skin Cancer\u003c\/strong\u003e program provides a concise yet practical review of one of the most rapidly evolving areas in dermatologic oncology.\u003c\/p\u003e\r\n\u003cp data-start=\"5983\" data-end=\"6237\"\u003eBy integrating current evidence, real-world clinical experience, treatment outcomes, and adverse event management strategies, this activity equips clinicians with the knowledge needed to optimize care for patients with advanced non-melanoma skin cancers.\u003c\/p\u003e\r\n\u003cp data-start=\"6239\" data-end=\"6466\"\u003eThe focused format makes this program particularly valuable for dermatologists, dermatologic surgeons, oncologists, and healthcare professionals seeking up-to-date guidance on the use of immunotherapy in skin cancer management.\u003c\/p\u003e\r\n \r\n\r\n\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eImmunotherapy for Non-Melanoma Skin Cancer.mp4\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Medical Amboss","offers":[{"title":"Default Title","offer_id":42979218522210,"sku":"MED-AMB09200","price":15.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/American-Society-for-Dermatologic-Surgery-Immunotherapy-for-Non-melanoma-Skin-Cancer.jpg?v=1780327321","url":"https:\/\/meducourse.com\/products\/american-society-for-dermatologic-surgery-immunotherapy-for-non-melanoma-skin-cancer","provider":"Meducourse","version":"1.0","type":"link"}